(Q39700748)

English

LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 September 2017

LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells (English)

1 reference

Europe PubMed Central

14 September 2017

apoptotic process

0 references

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

author name string

Raquel C Maia

1

1 reference

Europe PubMed Central

14 September 2017

Flavia C Vasconcelos

2

1 reference

Europe PubMed Central

14 September 2017

Thiago de Sá Bacelar

3

1 reference

Europe PubMed Central

14 September 2017

Eduardo J Salustiano

4

1 reference

Europe PubMed Central

14 September 2017

Luis Felipe R da Silva

5

1 reference

Europe PubMed Central

14 September 2017

Débora L Pereira

6

1 reference

Europe PubMed Central

14 September 2017

Arthur Moellman-Coelho

7

1 reference

Europe PubMed Central

14 September 2017

Chaquip D Netto

8

1 reference

Europe PubMed Central

14 September 2017

Alcides J da Silva

9

1 reference

Europe PubMed Central

14 September 2017

Vivian M Rumjanek

10

1 reference

Europe PubMed Central

14 September 2017

Paulo R R Costa

11

1 reference

Europe PubMed Central

14 September 2017

publication date

25 May 2010

1 reference

Europe PubMed Central

14 September 2017

Investigational New Drugs

1 reference

Europe PubMed Central

14 September 2017

29

1 reference

Europe PubMed Central

14 September 2017

6

1 reference

Europe PubMed Central

14 September 2017

1143-1155

1 reference

Europe PubMed Central

14 September 2017

https://scigraph.springernature.com/pub.10.1007/s10637-010-9453-z

0 references

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

Translation of the Philadelphia chromosome into therapy for CML.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

Resistance to imatinib mesylate in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

Imatinib resistance in CML.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

Loss of p53 impedes the antileukemic response to BCR-ABL inhibition

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

The inhibitor of apoptosis protein family and its antagonists in acute leukemias

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

(+/-)-3,4-Dihydroxy-8,9-methylenedioxypterocarpan and derivatives: cytotoxic effect on human leukemia cell lines

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

New pterocarpanquinones: synthesis, antineoplasic activity on cultured human malignant cell lines and TNF-alpha modulation in human PBMC cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

Multidrug resistance in tumour cells: characterization of the multidrug resistant cell line K562-Lucena 1.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

Pomolic acid-induced apoptosis in cells from patients with chronic myeloid leukemia exhibiting different drug resistance profile

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: a method validated by the laboratories of the French Drug Resistance Network

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

Modulation of reactive oxygen species by antioxidants in chronic myeloid leukemia cells enhances imatinib sensitivity through survivin downregulation.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

Survivin: a promising tumor biomarker

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

Differential subcellular localization of functionally divergent survivin splice variants.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

The effect of survivin on multidrug resistance mediated by P-glycoprotein in MCF-7 and its adriamycin resistant cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9453-Z

21 January 2018

Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20499132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20499132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/20499132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic discrimination in "good-risk" chronic granulocytic leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20499132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/20499132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Apoptosis regulators and their role in tumorigenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20499132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death

1 reference

https://pubmed.ncbi.nlm.nih.gov/20499132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protein measurement with the Folin phenol reagent

1 reference

https://pubmed.ncbi.nlm.nih.gov/20499132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differences in sensitivity to UVC, UVB and UVA radiation of a multidrug-resistant cell line overexpressing P-glycoprotein

1 reference

https://pubmed.ncbi.nlm.nih.gov/20499132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20499132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-010-9453-Z

1 reference

Europe PubMed Central

14 September 2017

1 reference

Europe PubMed Central

14 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39700748&oldid=2088981153"